Everest Medicines Acquires Exclusive Rights to VIS-101 for Serious Eye Disorders
Everest Medicines has acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic, in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
Partnership Details
The company has partnered with Visara, Inc., a subsidiary of NovaBridge Biosciences, to secure the exclusive license. The agreement includes an upfront payment of US$7 million and reimbursement of up to RMB24.0 million for prior expenses, with potential future payments of up to US$89 million.
This collaboration marks Everest's strategic expansion into ophthalmology, a high-potential therapeutic area.
Strategic Expansion
The acquisition strengthens Everest Medicines' late-stage product pipeline and core therapeutic portfolio, enriching its presence in the ophthalmology sector.
Author's summary: Everest Medicines expands into ophthalmology with VIS-101 license.